RxDoctor Payments Data

Jill Shafi

Psychiatric/Mental Health · Westampton, NJNPI 1194305425

Payments from drug & device makers

$2,159in general payments, 2019–2025

Across 122 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$786
  • Alkermes, Inc.$337
  • AbbVie$234
  • Teva Pharmaceuticals USA, Inc.$180
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$166
  • Neurocrine Biosciences, Inc.$123
  • plus $334 from 6 others

What the payments were for

  • Food & beverage$2,11298%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,159 in reported general payments places this provider in the 80th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$21,363
Medicare patients
119
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate97$291,572
IngrezzaValbenazine Tosylate12$102,845
AristadaAripiprazole Lauroxil23$68,228
Abilify MaintenaAripiprazole14$40,174
RexultiBrexpiprazole11$15,644
Lurasidone Hcl38$15,613
Aripiprazole63$11,039
Risperdal ConstaRisperidone Microspheres12$7,637
Divalproex Sodium ErDivalproex Sodium114$7,012
Clozapine41$6,223
Olanzapine159$4,956
Paliperidone ErPaliperidone20$4,177
Haloperidol62$3,289
Benztropine Mesylate162$2,389
Quetiapine Fumarate ErQuetiapine Fumarate16$1,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$786$299,209109 claims
Neurocrine Biosciences, Inc.Ingrezza$123$102,84512 claims
Alkermes, Inc.Aristada$337$68,22823 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$71$55,81825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Westampton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →